The above chart presents the market trend analysis for imexpharm from 2024 to 2025.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2025, the company has completed 10 transactions, with a transaction quantity of 2324.55 and a transaction weight of 0.
imexpharm is vietnam Buyer&Supplier,
and primarily engages in the import and export business of products such as ceftriaxone sodium,entercavir,neomycin sulphate.
According to the 52wmb.com global trade database, as of 2025-10-20, the company has completed 1508 international trades,
with its main trading regions covering india,china,spain etc.
The core products include HS29419000,HS29411019,HS70109040 etc,
often transported via ho chi minh city,port ho chi minh airport vn, port cat lai etc,
and its main trading partners are centrient pharmaceuticals nl b.v.,covalent laboratories pvt ltd.,alcapharm b.v..
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on imexpharm is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.